Oncologists discuss the selection of the optimal frontline therapy for renal cell carcinoma, considering factors like response rates, progression, quality of life, and long-term results.
First-in-Class PARP1 Selective Inhibitor Saruparib Shines in Phase 1 Trial of Advanced Solid Tumors
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
The Surprising Connection Between Male Infertility and Family Cancer Risk
FDA Approval Insights: Ponatinib in Ph+ ALL
Early Responses With CTX130 Renew Hope for Anti-CD70 CAR T-Cell Therapy in Advanced RCC
Vepdegestrant Shows Potential in ESR1-Mutant ER+/HER2– Breast Cancer
Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma
Prospective Data Reveal Most Young Survivors of Breast Cancer Could Successfully Give Birth
HPV Vaccinations Associated With Lower Rates of HPV-Caused Cancers in Patients Under 40 Years of Age
AI Virtual Navigation May Reengage Patients to Undergo Missed Colonoscopies